<DOC>
	<DOCNO>NCT02704403</DOCNO>
	<brief_summary>The primary objective study evaluate effect Elafibranor treatment compare placebo 1 ) histological improvement 2 ) all-cause mortality liver-related outcome patient nonalcoholic steatohepatitis ( NASH ) fibrosis .</brief_summary>
	<brief_title>Phase 3 Study Evaluate Efficacy Safety Elafibranor Versus Placebo Patients With Nonalcoholic Steatohepatitis ( NASH )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . Males female age 18 75 year inclusive first screen visit . 2 . Must provide sign write informed consent agree comply study protocol . 3 . BMI ≤45 kg/m² . 4 . Females participate study must either childbearing potential ( hysterectomy , bilateral oophorectomy , medically document ovarian failure , &gt; 50 year age cessation menses least 12 month due ovarian failure ) use efficient double contraception : hormonal contraception ( include patch , contraceptive ring , etc . ) , intrauterine device , mechanical contraception method + condom diaphragm spermicide full duration study 1 month end treatment . 5 . Histological confirmation steatohepatitis diagnostic liver biopsy central reading slide ( biopsy obtain within 6 month prior randomization screen period ) least 1 component NAS score ( steatosis score 03 , balloon degeneration score 02 , lobular inflammation score 03 ) . 6 . NAS score ≥4 . 7 . Fibrosis stage 1 great 4 , accord NASH CRN fibrosis stag system . 8 . Stable dose vitamin E , polyunsaturated fatty acid , ursodeoxycholic acid least 6 month prior diagnostic liver biopsy 9 . No change antidiabetic therapy within 6 month prior liver biopsy 1 . Known heart failure ( Grade I IV New York Heart Association classification ) . 2 . History efficient bariatric surgery within 5 year prior screen . 3 . Uncontrolled hypertension 4 . Type 1 diabetes patient . 5 . Patients decompensated diabetes ( HbA1c &gt; 9 % ) . 6 . Patients history clinically significant acute cardiac event within 6 month prior screen 7 . Weight loss 5 % within 6 month prior randomization 8 . Compensated decompensated cirrhosis 9 . Current recent history ( &lt; 5 year ) significant alcohol consumption 10 . Pregnant lactating female females plan become pregnant study period . 11 . Other well documented cause chronic liver disease accord standard diagnostic procedure 12 . Patients previous exposure Elafibranor 13 . Prohibited concomitant medication 14 . Any medical condition may diminish life expectancy le 2 year include known cancer . 15 . Evidence unstable untreated clinically significant immunological , endocrine , hematological , gastrointestinal , neurological , neoplastic psychiatric disease . 16 . Mental instability incompetence , validity inform consent ability compliant study uncertain .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Elafibranor</keyword>
	<keyword>NASH</keyword>
	<keyword>Nonalcoholic steatohepatitis</keyword>
	<keyword>Fatty liver disease</keyword>
	<keyword>Fibrosis</keyword>
</DOC>